# Lucence

> Lucence is a precision-health company founded in Singapore and headquartered in Palo Alto and Singapore. Its central bet is that a blood draw can reveal useful tumor signals - and that analyzing circulating RNA alongside DNA can catch actionable gene fusions a DNA-only test may miss. Its laboratories sell prescription molecular tests to oncologists, hospitals, insurers, researchers and, through physician-mediated screening, individuals.

- **Founded:** 2016
- **Headquarters:** Palo Alto, United States and Singapore
- **Founders:** Min-Han Tan (Founder, Chairman, CEO and Medical Director)
- **Products:** LiquidHALLMARK, LiquidHALLMARK CSF, LucenceINSIGHT, LiquidMARK, LucenceMONITOR
- **Notable:** Spun out from A*STAR in Singapore in 2016., Launched LiquidHALLMARK in 2018., Built CLIA-licensed, CAP-accredited laboratories in Singapore and Palo Alto.

## Products & services

- **LiquidHALLMARK** — Prescription liquid-biopsy assay that analyzes circulating tumor DNA and RNA for mutations and biomarkers used in therapy selection, clinical-trial matching and monitoring; Medicare covered for qualifying US patients with advanced cancer.
- **LiquidHALLMARK CSF** — US cerebrospinal-fluid NGS assay for resistance mutations in primary CNS tumors, leptomeningeal metastases and brain metastases.
- **LucenceINSIGHT** — Prescription multi-cancer early-detection blood test using ctDNA, ctRNA and viral DNA; US panels cover up to 12 cancers while international panels cover up to 50. A positive result requires confirmatory testing.
- **LiquidMARK** — Focused liquid-biopsy sub-panel for selected tumor types, available outside the United States.
- **LucenceMONITOR** — Blood test for recurrence and treatment-response monitoring across 15 solid tumor types, available outside the United States.
- **LumiRISK and LumiFOCUS** — Prescription hereditary-cancer panels; LumiRISK evaluates 45 genes linked to 11 cancers while LumiFOCUS offers cancer-specific panels outside the United States.
- **CardioHemeRISK** — NGS blood test for clonal hematopoiesis mutations associated with cardiac and hematological risk; it is a risk assessment, not a diagnosis.
- **LucenceLONGEVITY** — International combined preventive-health offering that packages LucenceINSIGHT 50 with CardioHemeRISK.
- **AmpliMARK** — Proprietary amplicon-based NGS and molecular-barcoding technology platform underlying Lucence's liquid-biopsy assays.

## Achievements

- Spun out from A*STAR in Singapore in 2016.
- Launched LiquidHALLMARK in 2018.
- Built CLIA-licensed, CAP-accredited laboratories in Singapore and Palo Alto.
- Became the first Asian-headquartered company reported to receive US Medicare coverage for a cancer liquid-biopsy test in 2023.
- Published the prospective, multicenter LIQUIK study in JCO Precision Oncology in 2025.
- LIQUIK found that adding ctRNA to Lucence's ctDNA assay detected 15.6% additional tissue-confirmed, guideline-recommended biomarkers among biomarker-positive metastatic nonsquamous NSCLC patients compared with an FDA-approved ctDNA-only test.
- Formed a strategic distribution collaboration with Mayo Clinic Laboratories in 2025.
- Expanded from cancer testing into multi-disease preventive-health assessment in 2025 and biological-age research translation in 2026.

## Latest updates

- **2025-01** — Mayo Clinic Laboratories and Lucence announced a strategic collaboration to expand access to LiquidHALLMARK.
- **2025-06** — The LIQUIK prospective multicenter comparison was published in JCO Precision Oncology.
- **2025** — Lucence expanded its portfolio with LucenceLONGEVITY and entered additional India and ASEAN markets.
- **2026-03** — Lucence highlighted CardioHemeRISK's use for detecting clonal hematopoiesis mutations as part of preventive cardiovascular and hematological risk assessment.
- **2026-08** — The company connected findings from the Singapore Longitudinal Ageing Studies, covering 5,409 people over an average 11.4 years, to a planned biological-age assessment tool.
- **2026-08** — Lucence updated LucenceINSIGHT with US panels covering up to 12 cancers and international options covering up to 50, with ctRNA enhancement for selected cancers.

## Links

- Website: https://www.lucence.com
- LinkedIn: https://www.linkedin.com/company/lucence
- Twitter/X: https://twitter.com/lucencedx
- Facebook: https://www.facebook.com/LucenceHealth

---

Profile page: https://yespress.io/lucence
Published by YesPress — https://yespress.io
Last updated: 2026-09-26